222 related articles for article (PubMed ID: 38089760)
1. Research progress in the establishment of pancreatic cancer models and preclinical applications.
Wu W; Wen K; Zhong Y
Cancer Innov; 2022 Oct; 1(3):207-219. PubMed ID: 38089760
[TBL] [Abstract][Full Text] [Related]
2. Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens.
Walters DM; Stokes JB; Adair SJ; Stelow EB; Borgman CA; Lowrey BT; Xin W; Blais EM; Lee JK; Papin JA; Parsons JT; Bauer TW
PLoS One; 2013; 8(10):e77065. PubMed ID: 24204737
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
5. Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
Torres MP; Rachagani S; Souchek JJ; Mallya K; Johansson SL; Batra SK
PLoS One; 2013; 8(11):e80580. PubMed ID: 24278292
[TBL] [Abstract][Full Text] [Related]
6. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
7. Cytology-based Detection of Circulating Tumour Cells in Human Pancreatic Cancer Xenograft Models With
Ito Y; Inoue E; Matsui Y; Kobuchi S; Moyama C; Amagase K; Yoshimura M; Ikehara Y; Nakata S; Nakanishi H
Anticancer Res; 2020 Dec; 40(12):6781-6789. PubMed ID: 33288571
[TBL] [Abstract][Full Text] [Related]
8. Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options.
Zhang CY; Liu S; Yang M
World J Gastroenterol; 2022 Dec; 28(48):6827-6845. PubMed ID: 36632312
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between miRNAs and signaling pathways involved in pancreatic cancer and pancreatic ductal adenocarcinoma.
Lotfi Z; Najjary S; Lotfi F; Amini M; Baghbanzadeh A; Rashid DJ; Asl ER; Baradaran B; Mokhtarzadeh A
Eur J Pharmacol; 2021 Jun; 901():174006. PubMed ID: 33711308
[TBL] [Abstract][Full Text] [Related]
10. High calpain-1 expression predicts a poor clinical outcome and contributes to tumor progression in pancreatic cancer patients.
Yu LM; Zhu YS; Xu CZ; Zhou LL; Xue ZX; Cai ZZ
Clin Transl Oncol; 2019 Jul; 21(7):924-932. PubMed ID: 30565085
[TBL] [Abstract][Full Text] [Related]
11. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy.
Erstad DJ; Sojoodi M; Taylor MS; Ghoshal S; Razavi AA; Graham-O'Regan KA; Bardeesy N; Ferrone CR; Lanuti M; Caravan P; Tanabe KK; Fuchs BC
Dis Model Mech; 2018 Jul; 11(7):. PubMed ID: 29903803
[TBL] [Abstract][Full Text] [Related]
12. HOXB5 promotes malignant progression in pancreatic cancer via the miR-6732 pathway.
Li ZX; Wu G; Jiang WJ; Li J; Wang YY; Ju XM; Yin YT
Cell Cycle; 2020 Jan; 19(2):233-245. PubMed ID: 31876226
[No Abstract] [Full Text] [Related]
13. Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma.
Zhang L; Sanderson SO; Lloyd RV; Smyrk TC
Am J Surg Pathol; 2007 Aug; 31(8):1191-5. PubMed ID: 17667542
[TBL] [Abstract][Full Text] [Related]
14. Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer.
Ehrenberg KR; Gao J; Oppel F; Frank S; Kang N; Dieter SM; Herbst F; Möhrmann L; Dubash TD; Schulz ER; Strakerjahn H; Giessler KM; Weber S; Oberlack A; Rief EM; Strobel O; Bergmann F; Lasitschka F; Weitz J; Glimm H; Ball CR
Cells; 2019 Feb; 8(2):. PubMed ID: 30744205
[TBL] [Abstract][Full Text] [Related]
15. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples.
Choi SI; Jeon AR; Kim MK; Lee YS; Im JE; Koh JW; Han SS; Kong SY; Yoon KA; Koh YH; Lee JH; Lee WJ; Park SJ; Hong EK; Woo SM; Kim YH
Front Oncol; 2019; 9():875. PubMed ID: 31572675
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
17. The lncRNA ENSG00000254041.1 promotes cell invasiveness and associates with poor prognosis of pancreatic ductal adenocarcinoma.
Chen B; Zhang Q; Wang X; Wang Y; Cui J; Zhuang H; Tang J
Aging (Albany NY); 2020 Feb; 12(4):3647-3661. PubMed ID: 32090981
[TBL] [Abstract][Full Text] [Related]
18. Establishment of Patient-derived Orthotopic Xenografts (PDX) as Models for Pancreatic Ductal Adenocarcinoma.
Magouliotis DE; Lafazanis K; Koutsougianni F; Sakellaridis N; Ioannou M; Zacharoulis D; Dimas K
In Vivo; 2022; 36(3):1114-1119. PubMed ID: 35478141
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
20. Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions.
Suri R; Zimmerman JW; Burkhart RA
Ann Pancreat Cancer; 2020 Dec; 3():. PubMed ID: 33889840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
